General form of registration statement for all companies including face-amount certificate companies

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.21.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Dec. 31, 2019
Cash flows from operating activities:        
Net loss $ (9,541,000) $ (7,697,000) $ (15,603,716) $ (18,498,341)
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation and amortization 367,000 432,000 867,000 949,006
Stock-based compensation 623,000 392,000 668,072 397,099
Non-cash interest expense 190,000 164,000 155,738 1,421,655
Change in fair value of preferred stock warrant liability 186,000 743,837 71,635
Non-cash portion of loss on debt extinguishment 161,000    
Allowance for doubtful accounts     (2,941)
Deferred rent 233,000 (104,000) (210,010) (217,756)
Changes in operating assets and liabilities:        
Accounts receivable (1,082,000) (613,000) (401,737) (126,200)
Prepaid expenses and other current assets 351,000 (98,000) (646,925) (38,950)
Deposits     (40,882)
Accounts payable 635,000 (131,000) (396,863) 373,747
Accrued expenses and other current liabilities (236,000) (475,000) 497,656 530,280
Deferred revenue 446,000 (608,000) (71,905) 644,961
Customer deposits     (108,750)
Net cash used in operating activities (7,853,000) (8,552,000) (14,398,853) (14,645,437)
Cash flows from investing activities:        
Purchase of property and equipment (318,000) (315,000) (647,015) (823,013)
Net cash used in investing activities (318,000) (315,000) (647,015) (823,013)
Cash flows from financing activities:        
Cash paid in connection with the Merger, net of cash acquired     (46,044)
Proceeds from loan 15,000,000    
Payment to unaccredited investors of Augmedix Operating Corporation (22,000) (555,174)
Proceeds of notes payable 2,180,000 2,180,300
Repayment of notes payable (12,966,000) (1,357,837)
Proceeds from sale of common stock     27,416,565
Proceeds from issuance of convertible preferred stock     499,999 15,271,440
Proceeds from issuance of convertible notes payable 500,000 3,303,535
Payment of financing costs (232,000) (4,000) (3,159,488) (52,893)
Proceeds from exercise of common stock warrants 4,000    
Proceeds from exercise of stock options 100,000 2,000 80,487 3,533
Net cash provided by financing activities 1,884,000 2,678,000 26,416,645 17,167,778
Effect of exchange rate changes on cash and restricted cash (1,000) (3,000) (1,176) (10,397)
Net increase/decrease in cash and restricted cash (6,288,000) (6,192,000) 11,369,601 1,688,931
Cash and restricted cash at beginning of period 22,972,986 11,603,385 11,603,385 9,914,454
Cash and restricted cash at end of period 16,685,000 5,411,000 22,972,986 11,603,385
Supplemental disclosure of cash flow information:        
Cash paid during the period for interest 830,000 708,000 1,265,608 1,367,929
Supplemental schedule of non-cash investing and financing activities:        
Fair value of warrants issued in connection with loan 395,000    
Fair value of common stock issued to service provider 600,000      
Property, plant, and equipment in accounts payable $ 21,000    
Conversion of convertible preferred stock to shares of common stock     54,242,264
Amounts due to unaccredited investors of Augmedix Operating Corporation     31,527
Financing fees in accrued expenses     5,000
Issuance of convertible preferred stock in exchange for convertible notes payable and accrued interest     3,319,283
Beneficial conversion feature related to convertible notes payable     $ 1,078,769